Search

Your search keyword '"Chenevix-Trench, G"' showing total 1,515 results

Search Constraints

Start Over You searched for: Author "Chenevix-Trench, G" Remove constraint Author: "Chenevix-Trench, G"
1,515 results on '"Chenevix-Trench, G"'

Search Results

151. Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature Communications, (2019), 10, 1, (431), 10.1038/s41467-018-08054-4)

152. Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia.

154. DNA mismatch repair gene MSH6 implicated in determining age at natural menopause

155. The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity

156. Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (vol 5, 4999, 2014)

157. Adult height is associated with increased risk of ovarian cancer: A Mendelian randomisation study

158. Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer

159. The BRCA2 c.68‐7T > A variant is not pathogenic:a model for clinical calibration of spliceogenicity

160. Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia

161. Abstract P5-10-01: Using whole genome sequencing and somatic mutation signatures to unravel insight into familial breast cancer aetiology

162. More on Co-Occurrence of COMT and BRCA1/2 Variants in a Population

164. Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study

165. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology

166. Heritable DNA methylation marks associated with susceptibility to breast cancer /631/67/69 /631/337/176/1988 /692/699/67/1347 /692/308/2056 /45 /45/61 article.

167. Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer

168. The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity

169. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.

170. Adult height is associated with increased risk of ovarian cancer: A Mendelian randomisation study

171. The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity

172. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

173. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

174. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

175. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology

176. Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.

177. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer

178. The BRCA2 c.68‐7T > A variant is not pathogenic:a model for clinical calibration of spliceogenicity

179. Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer

180. Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci

181. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores

182. Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer

183. Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers

184. No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival

185. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

186. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers

187. Body mass index and breast cancer survival: a Mendelian randomization analysis

188. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

189. Body mass index and breast cancer survival:a Mendelian randomization analysis

190. Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade

191. Risk of Ovarian Cancer and the NF-? B Pathway: Genetic Association with IL1A and TNFSF10

192. rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk

194. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

195. Abstract PD1-15: The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers

196. Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach

197. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes

198. RAD51B in familial breast cancer.

199. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

200. Body mass index and breast cancer survival

Catalog

Books, media, physical & digital resources